ArticleBMC cancer2026
The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multiparametric flow cytometry (MFC) is the core method for monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML), yet its clinical value during azacitidine-based maintenance therapy lacks sufficient real-world data support. This study retrospectively enrolled 129 AML patients who received azacitidine maintenance therapy at the First Hospital of Lanzhou University from January 2019 to May 2025, aiming to explore the aforementioned clinical value and related prognostic factors. The primary endpoints of the study were overall survival (OS), relapse-free survival (RFS), and disease-free survival (DFS); the secondary endpoints included time to MRD negativity, duration of MRD negativity, and the incidence of adverse events.The results showed that azacitidine-based maintenance therapy could bring significant clinical benefits to AML patients. MRD status and duration of response (DoR) during the maintenance phase were core prognostic biomarkers for AML patients receiving this treatment. Among them, the duration of MRD negativity was predictive of longer OS, DFS, and RFS, which could effectively reflect a robust therapeutic response and is recommended as a dynamic endpoint for evaluating maintenance therapy efficacy. In terms of safety, the incidence of serious adverse events in both the maintenance group and the control group was within a manageable range, with no intolerable safety issues. In conclusion, azacitidine-based maintenance therapy for AML has a favorable benefit-risk ratio, and MRD-related indicators can serve as key reference criteria for evaluating the efficacy and prognosis of this treatment regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.